Preclinical News and Research

RSS
New research collaboration aims to develop better therapies for autoimmune diseases

New research collaboration aims to develop better therapies for autoimmune diseases

EU-funded project aims to identify potential new targets for cancer therapy

EU-funded project aims to identify potential new targets for cancer therapy

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Scientists use mice to replicate aspects of human breast cancer to find cure among women

Scientists use mice to replicate aspects of human breast cancer to find cure among women

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

NIH study finds that MDMA drug can be more dangerous in hot, crowded settings

NIH study finds that MDMA drug can be more dangerous in hot, crowded settings

New book documents groundbreaking studies on modified citrus pectin

New book documents groundbreaking studies on modified citrus pectin

KineMed renews non-exclusive research collaboration with Pfizer

KineMed renews non-exclusive research collaboration with Pfizer

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

NeuroVive extends collaboration with Hospices Civils de Lyon

NeuroVive extends collaboration with Hospices Civils de Lyon

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.